Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

被引：2

作者：

Ionova, Tatyana ^{[1
,2
]}

Afanasiev, Boris ^{[3
]}

Andrievskih, Maria ^{[4
]}

Amdiev, Alim ^{[5
]}

Baryakh, Elena A. ^{[6
]}

Chang, Viktor ^{[7
]}

Husainova, Gulnara ^{[8
]}

Ivanov, Vladimir ^{[9
]}

Kaplanov, Kamil D. ^{[10
]}

Kaverina, Oksana ^{[11
]}

Klitochenko, Tatiana ^{[10
]}

Kurakin, Vyacheslav ^{[12
]}

Larionova, Olga ^{[13
,16
,18
]}

Lazareva, Darya ^{[11
]}

Lepik, Kirill ^{[14
]}

Lysenko, Irina ^{[15
]}

Mikhailova, Nataliia ^{[14
]}

Minullina, Raisa ^{[8
]}

Mironov, Oleg

Misyurina, Elena ^{[6
]}

Mochkin, Nikita ^{[17
]}

Nikitina, Tatiana ^{[1
,2
]}

Osipov, Iurii ^{[9
]}

Petrova, Tatiana ^{[8
]}

Porfirieva, Natalia ^{[1
]}

Rykavitcin, Oleg

Safin, Rustem ^{[8
]}

Shelekhova, Tatiana ^{[19
]}

Sherstnev, Dmitrij ^{[19
]}

Simashova, Polina ^{[18
]}

Smirnova, Elena ^{[17
]}

Trenina, Natalia ^{[12
]}

Vasiliev, Evgeniy V. ^{[20
]}

Volkov, Mikhail ^{[13
]}

Volodicheva, Elena ^{[21
]}

机构：

[1] Multinatl Ctr Qual Life Res, St Petersburg, Russia

[2] St Petersburg State Univ Hosp, St Petersburg, Russia

[3] First State Pavlov Med Univ St Petersburg, Raisa Gorbacheva Mem Res Inst Paediat Oncol Hemat, St Petersburg, Russia

[4] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[5] VM Efetov Crimean Republican Oncol Ctr, Simferopol, Ukraine

[6] City Clin Hosp 52, Moscow, Russia

[7] Tambov Reg Oncol Clin Ctr, Tambov, Russia

[8] Minist Hlth Republ Tatarstan, Republican Clin Oncol Ctr, Kazan, Russia

[9] Almazov Natl Med Res Ctr, St Petersburg, Russia

[10] Reg Clin Oncol Dispencary, Volgograd, Russia

[11] Altai Reg Oncol Ctr, Barnaul, Russia

[12] Clin Oncol Ctr, Omsk, Russia

[13] Primorskiy Reg Oncol Ctr, Vladivostok, Russia

[14] Pavlov First St Petersburg State Med Univ, Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg, Russia

[15] Rostov Sci Res Inst Oncol, Rostov Na Donu, Russia

[16] Tambov Reg Oncol Clin Ctr, Tambov, Russia

[17] NI Pirogov Natl Med Surg Ctr, Moscow, Russia

[18] NN Burdenko Principal Mil Clin Hosp, Moscow, Russia

[19] Saratov State Med Univ, Clin Profess Pathol & Hematol, Saratov, Russia

[20] Reg Clin Hosp, Krasnoyarsk, Russia

[21] Reg Clin Hosp, Tulsa, Russia

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-121997

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5296

引用

页数：4

共 50 条

[1] Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma
Zsuzsa, Molnar
Imre, Pinczes Laszlo
Klara, Piukovics
Ildiko, Istenes
Krisztina, Wolf
Zoltan, Csukly
Arpad, Szomor
Arpad, Illes
Zsofia, Miltenyi
ORVOSI HETILAP, 2017, 158 (41) : 1630 - 1634
[2] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
Chen, Runzhe
Chen, Baoan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
[3] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
Zinzani, Pier Luigi
Derenzini, Enrico
Pellegrini, Cinzia
Celli, Monica
Broccoli, Alessandro
Argnani, Lisa
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
[4] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Paydas, S.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, Z. A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Ferhanoglu, B.
ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
[5] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Siddiqi, Tanya
Thomas, Sandra H.
Chen, Robert
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85
[6] REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA
Stefoni, V.
Pulsoni, A.
Rigacci, L.
Patti, C.
Gini, G.
Mannina, D.
Tani, M.
Rusconi, C.
Romano, A.
Vanazzi, A.
Botto, B.
Santoro, A.
Hoaus, S.
Rigolin, G. M.
Pellegrino, M.
Mazza, P.
Molica, S.
Corradini, P.
Fama, A.
Gaudio, F.
Merli, M.
Ronconi, F.
Gritti, G.
Vallisa, D.
Tosi, P.
Liberati, A. M.
Pinto, A.
Pavone, M. C. V.
Gherlinzoni, F.
Bianchi, M. P.
Volpetti, S.
Trentin, L.
Goldaniga, M.
Bonfichi, M.
De Renzo, A.
Schiavotto, C.
Spina, M.
Carella, A. M.
Argnani, L.
Zinzani, P. L.
HAEMATOLOGICA, 2017, 102 : 29 - 29
[7] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
A. Salihoglu
T. Elverdi
I. Karadogan
S. Paydas
E. Ozdemir
G. Erdem
N. Karadurmus
G. Akyol
L. Kaynar
ZA Yegin
G. Sucak
V. Ozkocaman
P. Topcuoglu
M. Ozcan
E. Birtas
H. Goker
Z. Baslar
B. Ferhanoglu
Annals of Hematology, 2015, 94 : 415 - 420
[8] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
Ferhanoglu, B.
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Paydas, S.
HAEMATOLOGICA, 2014, 99 : 675 - 676
[9] Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study
Massano, Davide
Carraro, Elisa
Mussolin, Lara
Buffardi, Salvatore
Barat, Veronica
Zama, Daniele
Muggeo, Paola
Vendemini, Francesca
Sau, Antonella
Moleti, Maria Luisa
Verzegnassi, Federico
D'Amico, Salvatore
Casini, Tommaso
Garaventa, Alberto
Schiavello, Elisabetta
Cellini, Monica
Vinti, Luciana
Farruggia, Piero
Perruccio, Katia
Cesaro, Simone
De Santis, Raffaela
Marinoni, Maddalena
D'Alba, Irene
Mura, Rosa Maria
Burnelli, Roberta
Mascarin, Maurizio
Pillon, Marta
PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
[10] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Mei, Matthew
Tsai, Ni-Chun
Palmer, Joycelynne
Armenian, Saro
Chen, Robert
Rosen, Steven
Forman, Stephen
Popplewell, Leslie
Kwak, Larry
Martin, Peter
Maddocks, Kami
Bond, David
Herrera, Alex F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542

← 1 2 3 4 5 →